Hepatocellular Carcinoma Clinical Trials (April 2026): 684 Recruiting Interventional Studies

Last updated: April 18, 2026

Current Clinical Trial Landscape

Recruiting Trials by Treatment Setting

Neoadjuvant / Adjuvant (Around Surgery or Transplant)

Immunotherapy before/after resection to reduce recurrence — a rapidly growing area:

• Neoadjuvant:
  • NCT07475026 - Neoadjuvant tislelizumab + lenvatinib in resectable HCC at high recurrence risk (Phase 3)
  • NCT07461675 - Neoadjuvant immunotherapy effects on anti-tumour immunity in HCC (Phase 3)
  • NCT07027436 - RT + durvalumab + tremelimumab + surgery vs surgery alone (Phase 3)
• Adjuvant:
  • NCT07417397 - Adjuvant TACE in HCC with high-risk recurrence factors (Phase 3)
  • NCT07186621 - Adjuvant RT + sintilimab vs TACE for HCC (Phase 3)

Intermediate Stage — TACE Combinations

TACE plus systemic therapy is transforming intermediate HCC treatment after LEAP-012 and EMERALD-1 results:

• • NCT06485466 - TACE + camrelizumab + apatinib for unresectable HCC (Phase 3)
  • NCT07309419 - TACE + oral triple-agent cocktail vs TACE + placebo (Phase 3)
  • NCT07302919 - TACE + ABCB1 inhibition vs TACE alone (Phase 3)
  • NCT07322848 - DEB-TACE vs cTACE in HCC after TIPS (Phase 3)

Advanced / Metastatic — First-Line

Immunotherapy combinations are standard. Trials test new IO combos, HAIC additions, and novel agents:

• IO combinations:
  • NCT07490262 - IBI310 + sintilimab combination for advanced HCC (Phase 3)
  • NCT06921785 - Rilvegostomig + bevacizumab ± tremelimumab (Phase 3)
  • NCT06680258 - TPST-1120 + atezolizumab + bevacizumab (Phase 3)
• HAIC + systemic therapy:
  • NCT07267806 - Camrelizumab + apatinib ± FOLFOX chemotherapy (Phase 3)
  • NCT06172205 - FOLFOX + camrelizumab + apatinib vs HAIC-FOLFOX + camrelizumab + apatinib (Phase 3)
  • NCT06904170 - Durvalumab + tremelimumab ± HAIC (Phase 3)

Advanced — Second-Line and Beyond

After first-line IO failure, options include TKIs and novel agents:

• • NCT07392866 - SH006 + combination therapy vs regorafenib (Phase 3)
  • NCT06108272 - Livmoniplimab (anti-TIGIT) + atezolizumab + bevacizumab (Phase 3)
  • NCT05317819 - ADI-PEG 20 vs placebo in high-arginine unresectable HCC (Phase 3)

Locoregional Approaches

SBRT, Y-90 radioembolization, and ablation — often combined with systemic therapy:

• • NCT07293468 - SBRT vs SIRT + combination IO for unresectable HCC (Phase 3)
  • NCT07166406 - Immunotherapy ± SBRT in HCC (Phase 3)
  • NCT07381660 - SBRT vs surgical resection for small HCC (Phase 3)

Prevention

• • NCT07529262 - AspiRe HCC: Aspirin to reduce HCC risk in cirrhosis (Phase 3)

Showing selected notable trials. View all 684 recruiting interventional trials on ClinicalTrials.gov.

Frequently Asked Questions